anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Clozapine is an antipsychotic used for treatment-resistant schizophrenia with a significant side effect profile, including agranulocytosis, myocarditis and fever. Clozapine-induced fever often occurs in the first 2 weeks of treatment and settle after a few days. We report a case of a woman in her mid-30s who developed fever and infective symptoms suggestive of an atypical pneumonia while on clozapine titration. She was on clozapine for 16 days before developing high-grade fever, dry cough, diarrhoea, headache and photophobia with a very high CRP. We performed an extensive infection workup that returned negative results except for bilateral upper lobe ground glass changes of the lungs on CT. Despite antibiotic therapy, which would cover an atypical pneumonia, her CRP remained elevated and her fever persisted. Focus was directed to clozapine-induced pneumonitis as the cause for her symptoms. Her antibiotics were ceased, and clozapine was downtitrated. With the adjustment of her clozapine dose, her fevers and associated symptoms resolved, and CRP downtrended. Her fevers did not return when clozapine was uptitrated in the community subsequently. Clozapine-induced fever or other immune-allergic reactions should be systematically considered when patients develop fever during the initiation phase of clozapine therapy. Ruling out infective causes is desirable prior to attributing fevers to clozapine especially when they are accompanied by infective symptoms and high inflammatory markers. Careful downtitration of clozapine should be considered rather than abrupt cessation in managing clozapine-induced fevers and subsequent slow uptitration could be considered.
Long-term surveillance. Colonoscopy at 10 years in low-risk adenomas or 5 years in high-risk adenomas.
This arm, Standing workstation - second 8 weeks, received the intervention of a standing workstation for 8 weeks of the study. For the first 8 weeks, the worked at their normal desks without an intervention. The second 8 weeks they received a standing workstation and their use was monitored.
FIELD: medicine, phytotherapy. SUBSTANCE: plant-base biologically active addition showing adaptogenic effect has common chicory as a base and additional enhancing and corrective components taken among the following medicinal plants: amaranthus, barberry, birch, cow-parsnip Sibirica, black elder, common garden angelica, European dewberry, European wood strawberry, umbellate centaury, maize, silver- -weed cinquefoil, common burdock, alfalfa, common juniper, wild carrot, planted carrot, oat, medicinal dandelion, mistletoe, walnut, aspen, common plantain, common wormwood, creeping wheat-grass, common agrimony, black currant, medicinal caraway, bean, field horse-tail, sandy everlasting, common bilberry and cinnamon rose; antiseptics and preserving agents (spring water, silver water, European cranberry juice) and bee honey from mixed grass in the following ratio of components, p. p.: common chicory, 1; enhancing and corrective substances, 4; spring water, 66; silver water, 7; cranberry juice, 34 and honey from mixed grass, 16. Proposed adaptogen improves function of pancreas and its insulin-producing activity, recoveries functions of other blood glands by mediated mechanism that results to normalization of metabolism and enhances immune defense system of human body from pathological effect of microorganisms, viruses and protozoan. Invention can be used for prophylaxis and enhancement of weakened immunity. EFFECT: enhanced effectiveness of addition. 1 tbl
PURPOSE: A composition containing essential oil isolated from plants is provided to effectively suppress tyrosinase activation and melanogenesis. CONSTITUTION: A composition for skin whitening contains 0.01-50 wt% of plant essential oil isolated from Artemisia argyi Lev. et Vant., Citrus limonum, Foeniclum vulgare, or pine needles as an active ingredient. The composition is a cosmetic composition or pharmaceutical composition. The cosmetic composition is manufactured in the form of a skin softener, astringent, lotion, milk lotion, moisture lotion, massage cream, nutrition cream, hand cream, essence, pack, soap, cleansing foam, body lotion, or body cleanser. The pharmaceutical composition is manufactured in the form of a cream, gel, patch, spray, ointment, liniment, paster, or cataplasma.
FIELD: biotechnology. SUBSTANCE: strain of Bifidobacterium bifidum VKPM Ac-1578 shows broad spectrum of resistance to antibiotics, high adhesion, absence of bactericidal activity to other species of bifidobacteria. Properties of the strain are stable and do not change under storage, in the process of culturing and under effect of extreme factors. Invention can be used in medicine for preparing bacterial preparations and as autostrain for preparing preparation of probiotic of individual prescription and in food industry in production of milk fermented products and BАD. EFFECT: strain indicated above, valuable properties of strain. 3 tbl, 2 ex
A purified protein designated ULIP 6, comprising the 564 amino acid sequence fully defined in the specification, or its epitope, is new. A purified protein designated ULIP 6, comprising the 564 amino acid sequence fully defined in the specification, or its epitope, is new. The epitope has the following sequence: KEMGTPLADTPTRPVTRHGGC. Independent claims are also included for the following: (1) an isolated nucleic acid comprising a sequence encoding ULIP6 or its epitope; (2) an isolated nucleic acid comprising the 1218 nucleotide (nt) sequence fully defined in the specification or nucleotides 1-162 of the 3074 nt sequence fully defined in the specification; (3) a cloning or expression vector comprising the nucleic acid of (1) or (2); (4) a host cell transformed with the vector of (3); (5) antibodies, their chimeras, fragments or immuno-conjugants obtained using ULIP6 or its epitope; (6) detecting or purifying ULIP6 protein or its epitope using the above antibody; (7) detecting anti-CV2 antibodies using the above ULIP6 protein or its epitope in a biological sample; (8) diagnosing paraneoplastic neurological syndromes or cancerous tumor formation comprising contacting a biological sample with ULIP6 protein or its epitope and detecting formed complexes. ACTIVITY : Nootropic; cytostatic. No biological data given. MECHANISM OF ACTION : None given.
A total of 148 patients with endometrial cancer and atypical endometrial hyperplasia were included in the training set of the prediction model. They were divided into progesterone sensitive group and progesterone insensitive group.
All study participants in this arm will receive hypofractionated whole pelvic radiation treatment for a shortened time period of 3-5 weeks. The goal of this arm is to establish a safe and tolerable dose of shortened (hypofractionated) pelvic radiation treatment for study participants. Once a safe and tolerable dose is established for this shortened form of radiation treatment, participants who meet criteria for the second phase of this study will participate in an expansion cohort that will explore the efficacy (how effective shortened/hypofractionated radiation treatment is for treating endometrial cancer).
NEW MATERIAL:A compound expressed by formula 1 (R<1> is protecting group of the N atom; R<3> is H or protecting group of OH). EXAMPLE:trans-1-(2,4-Dimethoxybenzyl)-3-(1'-acetoxyethyl)-4-carboxymet hylazeti dine-2-one. USE:A synthetic intermediate for carbapenem derivatives capable of exhibiting excellent antimicrobial activity against a wide range of pathogenic germs. PREPARATION:The carboxy group of a compound expressed by formula 2 (R<4> is carboxyl-protecting group, e.g. alkyl, halogenoalkyl, aralkyl, etc.) is removed to give a compound expressed by formula 3 and the protecting group of the carboxy group is removed (a base is added and treatment is carried out at -50-+100 deg.C when R<4> is alkyl) to give a compound expressed by formula 4. The resultant compound expressed by formula 4 is then reacted with a halogenating agent to afford a solution of a compound expressed by formula 5 (X is halogen), which is then added to a solution of an excess diazomethane in ether and reacted at -50-+30 deg.C to provide a diazoketone derivative expressed by formula 6. The obtained compound expressed by formula 6 is the irradiated with light to give the aimed compound expressed by formula I.
Two sponges of collagen-gentamicin will be inserted into the hip immediately before closure of the wound. Each sponge (10 by 10 cm) contains 280 mg of collagen and 130 mg of gentamicin.
In this group, the treating attending physician will be free to make rest recommendations as they see fit. An internal survey of physician practice found that the vast majority of physicians instruct patients rest for 1-2 days, then to return to school and physical activity after the patient's symptoms have resolved. The amount of rest will vary from patients to patient based on variation in symptom resolution and patient compliance. This advice is consistent with best practices outlined by the CDC.
Gestational diabetes mellitus (GDM) is characterized by insulin resistance and low-grade inflammation, and most studies have demonstrated gut dysbiosis in GDM pregnancies. Overall, they were manifested as a reduction in microbiome diversity and richness, depleted short chain fatty acid (SCFA)-producing genera and a dominant of Gram-negative pathogens releasing lipopolysaccharide (LPS). The SCFAs functioned as energy substance or signaling molecules to interact with host locally and beyond the gut. LPS contributed to pathophysiology of diseases through activating Toll-like receptor 4 (TLR4) and involved in inflammatory responses. The gut microbiome dysbiosis was not only closely related with GDM, it was also vital to fetal health through vertical transmission. In this review, we summarized gut microbiota signature in GDM pregnancies of each trimester, and presented a brief introduction of microbiome derived SCFAs. We then discussed mechanisms of microbiome-host interactions in the physiopathology of GDM and associated metabolic disorders. Finally, we compared offspring microbiota composition from GDM with that from normal pregnancies, and described the possible mechanism.
All participants/caregivers will be asked for consent for point-of-care (POC) blood C-reactive protein (CRP), nasopharyngeal swab for virology/Mycoplasma testing, and urine for pneumococcal antigen (UAg) testing, but, since this testing will not affect care, these are optional (ie. refusal will not preclude enrolment). The RA will phone the caregiver at Day 2-5, Day 14-21, and Day 30 post-enrollment, for outcome ascertainment. Caregivers will be asked to fill out a daily diary (either electronically or on paper) to record the participant's symptoms, clinical progress, and possible drug adverse effects. Caregivers will also be instructed on how to take patient temperature. All participants whose symptoms do not progressively improve will be encouraged to return to the ED to be reassessed, as per standard of care.
Forensic pathologists need to have comprehensive knowledge of a large variety of causes of sudden natural death. We describe a case of sudden and unexpected death in woman in her sixties due to rupture of a large paraesophageal hematoma. The post-mortem examination and differential diagnosis are discussed. The combined findings of whole-body post-mortem CT imaging (PMCT), targeted PMCT angiography, autopsy, and histology are most in keeping with 'esophageal apoplexy'; a rare cause of hemorrhage in the esophageal wall. A review of the literature indicates that most cases of esophageal apoplexy are self-limiting and that fatal complications are exceedingly rare. Our case demonstrates that esophageal apoplexy can present as sudden unexpected death.
PURPOSE: This study is to evaluate the correlation between retrobulbar perfusion deficits and glaucomatous visual field defects.
METHODS: Eighty-four patients with glaucoma and 17 normal subjects serving as controls were selected. Color Doppler imaging (CDI) was used to measure the changes in blood flow parameters in the retrobulbar ophthalmic artery (OA), central retinal artery (CRA), and short posterior ciliary arteries (SPCAs). Visual field testing was performed using a Humphrey perimeter, categorizing the visual field deficits into four stages according to the Advanced Glaucoma Intervention Study (AGIS) scoring method. Subsequently, the correlation of retrobulbar hemodynamic parameter alterations among glaucomatous patients with varying visual field defects was examined.
RESULTS: The higher the visual field stage, the lower the peak systolic velocity (PSV) of the OA, CRA, and SPCAs in glaucomatous patients. The CRA had the highest sensitivity to changes in its PSV. The PSV of the temporal SPCA (TSPCA-PSV) was lower in advanced glaucoma than in early-stage glaucoma. The PSVs of the OA, CRA, and TSPCA, as well as the resistance index of the CRA (CRA-RI), were positively correlated with the visual field index and the mean deviation. Except for that of OA, the PSV of the retrobulbar vessels was negatively correlated with the pattern standard deviation (PSD). The OA-PSV and end-diastolic velocity (EDV) of the CRA and TSPCA were lower in patients with superior visual field defects than in those with inferior visual field defects.
CONCLUSIONS: Greater severity of visual field defects corresponded to poorer retrobulbar blood flow in glaucomatous patients. Patients suffered significant perfusion impairments in the CRA at the early stage, accompanied by SPCA perfusion disorder at the advanced stage. The presence of a bow-shaped defect in the superior or inferior region of the visual field in moderate-stage glaucoma was closely correlated with retrobulbar vascular EDV.
TRIAL REGISTRATION: ChiCTR2200059048 (2022-04-23).
As per the wishes of the Dept. of the Army and Walter Reed Army Medical Center Dept. of Clinical Investigation, patients will be randomized in a 3:1 ratio to receive 2 transforaminal epidural etanercept or saline injections at 2-week intervals. Both patients and physicians will be blinded as to the injectate and treatment group. There will be 3 study groups. Group I will receive either 2 mg of etanercept or saline per injection. Group II will receive either 4 mg of etanercept or saline per injection. Group III will receive either 6 mg of etanercept or saline per injection. In each group there will be 8 patients: 6 who receive etanercept and 2 who receive saline. As per a previous study we just completed, etanercept doses will not be escalated until all 6 patients have completed their 1-month follow-up visits without any evidence of toxicity or complications.
PURPOSE OF REVIEW: In this report, we summarize why the availability of cystatin C is important across a variety of clinical scenarios, the recent literature on when, why and in whom cystatin C testing should be considered, and how nephrologists can take practical steps to incorporate cystatin C testing into their practice.
RECENT FINDINGS: Large intra-individual discrepancies between estimated glomerular filtration rate by creatinine (eGFRcr) and estimated glomerular filtration rate by creatinine eGFRcys (known as eGFRdiff) are observed in at least 1 in 4 people. These differences are seen more commonly among more vulnerable individuals: older adults, females, non-White individuals and those living with multiple medical conditions. A large eGFRdiff, where eGFRcys is lower than eGFRcr, is associated with a plethora of adverse outcomes, including medication-associated adverse events, acute kidney injury, cardiovascular disease, kidney failure and all-cause mortality. Among studies that have measured GFR, eGFRcr-cys usually provides the most accurate estimation of kidney function compared to mGFR, including among participants with large discrepancies between eGFRcr and eGFRcys.
SUMMARY: Cystatin C improves sensitivity and specificity of chronic kidney disease diagnosis, improves detection of harmful acute and chronic changes in kidney function, improves precision of treatment eligibility and safety, and may reduce healthcare inequalities. Better education, curiosity, and motivation among nephrologists could substantially improve the availability and utilization of cystatin C.
Subjects with non-small cell lung cancer will be treated concurrently every 6 weeks with INBRX-106 0.1 mg/kg and 200 mg pembrolizumab IV every 3 weeks. This is one of the randomized cohorts.
Participants first received Favir 200 mg FT manufactured by Kocak in a fasting state. After a washout period of 48 hours, they then received Avigan FT200 mg manufactured by Toyama Chemical Industry Co.Ltd./ Japan in a fasting state.
PURPOSE: A systematic review and meta-analysis for incidence and risk factors of new-onset sacroiliac joint pain (SIJP) after spinal surgery aimed to provide evidence-based medical references for its early prevention, timely intervention, and appropriate treatment.
METHODOLOGY: The protocol of the systematic review and meta-analysis was registered in the International Prospective Register of Systematic Review (PROSPERO) with the PROSPERO ID (CRD42023463177). Relevant studies were searched to January 2024 from the databases of PubMed, Embase, Cochrane Library, and Web of Science, and the types of studies were cohort studies, case-control studies, and cross-sectional studies. Study quality was assessed using the Newcastle-Ottawa Scale (NOS) and the Cross-Sectional/Prevalence Study Quality recommended by the Agency for Healthcare Research and Quality (AHRQ). Two authors conducted studies search, data extraction, and quality assessment independently. Meta-analyses were done using Stata 14.0 software.
RESULTS: Twelve observational studies with 3,570 spinal surgery patients were included. Ten were case-control studies, one was a cross-sectional study, and another was a cohort study, all of which were of moderate quality and above. The results of the meta-analysis showed that the incidence of new-onset SIJP after spinal surgery was 9.40%; females, no. of surgical segments, fusion to the sacrum, and postoperative pelvic tilt (PT) were significantly associated with the new-onset SIJP after spinal surgery. Meta-analyses for preoperative and postoperative controls of spondylopelvic parameters showed that postoperative lumbar lordosis (LL) in the SIJP group and postoperative LL and sacral slope (SS) of patients in the NoSIJP group had significant differences from preoperative.
CONCLUSION: Available evidence suggests that an increased risk of new-onset SIJP after spinal surgery is associated with sex, multi-segmental surgery, fusion to the sacrum, and greater postoperative PT.
A cross-sectional survey will be completed by 418 participants from several administrative regions of Québec (Canada). A special effort will be made to recruit men and women with low socioeconomic status (SES), but without rejecting adults from middle/high SES. First, 325 adults from low SES (high school or less and gross annual household income \< $55,000 canadian) and from several administrative regions of Québec will be identified by a survey firm. In addition, an e-mail mailing list from the Institute of Nutrition and Functional Food (INAF, Laval University) will be used to distribute the recruitment ad to complete our sample (n=93 from all SES).

The survey is based on the Theory of Planned Behaviour and assesses intention to participate in NutriQuébec as well as attitude, subjective norm, and perceived behavioural control. The salient beliefs underlying the determinants of individual's intention to participate in the NutriQuébec study most frequently cited in the focus groups (from a preliminary elicitation study: 2018-042 A-1/18-05-2018) were used to develop the survey questions. The survey also assesses the preferences regarding the recruitment. Sociodemographic questions are also asked.
FluMist/B/Victoria was administered intranasally using a BD Accuspray™ device. A total volume of 0.2 mL was administered intranasally (approximately 0.1 mL into each nostril). Each dose contained 10\^7.0 ± 0.5 FFU of each of 3 cold-adapted, temperature-sensitive, attenuated, 6:2 reassortant influenza virus strains: A/H1N1 (A/South Dakota/6/2007), A/H3N2 (A/Uruguay/716/2007), and B/Victoria (B/Malaysia/2506/2004).
The preparation of the TICE BCG suspension should be done using aseptic technique. To avoid cross-contamination, parenteral drugs should not be prepared in areas where BCG has been prepared. A separate area for the preparation of the TICE BCG suspension is recommended. All equipment, supplies, and receptacles in contact with TICE BCG should be handled and disposed of as biohazardous. The pharmacist or individual responsible for mixing the agent should wear gloves and take precautions to avoid contact of BCG with broken skin. If preparation cannot be performed in a biocontainment hood, then a mask and gown should be worn to avoid inhalation of BCG organisms and inadvertent exposure to broken skin.

Draw 1 mL of sterile, preservative-free saline (0.9% Sodium Chloride Injection USP) at 4–25°C into a small syringe (e.g., 3 mL) and add to 1 vial of TICE BCG to resuspend. Ensure that the needle is inserted through the center of the rubber stopper of the vial. Gently swirl the vial until a homogenous suspension is obtained. Avoid forceful agitation which may cause clumping of the mycobacteria.

Dilute the cloudy TICE BCG suspension in sterile, preservative-free saline to a final volume of 50 mL. Mix the suspension gently prior to intravesical instillation.

The reconstituted TICE BCG should be kept refrigerated (2–8°C), protected from exposure to direct sunlight, and used within 2 hours. Discard unused portion.

Note: DO NOT filter the contents of the TICE BCG vial. Precautions should be taken to avoid exposing the TICE BCG to direct sunlight. Bacteriostatic solutions must be avoided. In addition, use only sterile, preservative-free saline, 0.9% Sodium Chloride Injection USP as diluent.